The agency has been brought on board to support the European launch of its metastatic breast cancer treatment Abraxane. The initial focus of the launch will be in the UK and Germany.
College Hill's remit includes both corporate and product-based public and media relations. The account will be headed up by Life Sciences managing partner Sue Charles.
Abraxane is the world's first and only albumin bound nanoparticle chemotherapeutic compound, which is based on its proprietary tumour targeting system known as the nab platform.
Abraxane has been approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of patients with metastatic breast cancer.
